Objectives: Intermittent celecoxib use reduces drug cost and limits risk of adverse events, but mitigates drug efficacy. The objective of this study was to estimate the cost-effectiveness of continuous versus intermittent celecoxib use among patients with progressive and symptomatic osteoarthritis. MethOds: Number of flares per patient were derived using graph digitization of a pragmatic clinical trial that assessed the efficacy of continuous versus intermittent celecoxib. Monte-Carlo simulation with bootstrapping was developed using Poisson distribution for treatment over one year. The simulation estimated the proportion of patients for each cumulative number of flares, assumed to be distributed uniformly over the study period. Continuous use patients received 200 mg daily celecoxib and additional 200 mg after flare occurrence; intermittent use patients received 400mg daily celecoxib only when flares occurred. The model also considered additional physician visits, productivity loss, and health utility associated with flares. Risk and cost of hip/knee surgery were considered in a sensitivity analysis. Costs were reported in 2017 Chinese Yuan (¥). Results: Patients with continuous celecoxib use had 38.5% reduction in flares over one year compared with intermittent use (mean±SE [95%
S75the United States (US). MethodS: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model was used to assess the costs (2017 US dollars) and qualityadjusted life-years (QALYs) associated with SGLT2i or GLP-1RA add-on therapy in T2D after metformin failure. The model was run over 3-and 5-year time horizons from a US payer perspective. The UKPDS Outcomes Model predicts diabetes-related outcomes, including: ischemic heart disease, chronic heart failure, amputation, blindness, renal failure, stroke, myocardial infarction, and death. Baseline characteristics were derived from published literature. Simulated hemoglobin A1c (A1C) reductions for the first two years of the model were obtained from long-term outcomes studies and were extrapolated using the model's default algorithm. Costs were obtained from RedBook for drugs and US national sources and published literature for others. Utilities were obtained from published literature. Costs and QALYs were discounted 3% annually. ReSultS: At 5 years, SGLT2i dominated GLP-1RA; SGLT2i cost $66,000 and yielded 3.54 QALYs, whereas GLP-1RA cost $91,000 and yielded 3.54 QALYs. Despite a greater initial reduction in A1C, GLP-1RA had a greater increase in A1C at two years in published clinical trials, which resulted in similar modeled mean A1C values at five years (SGLT2i 7.75% vs. GLP-1RA 7.64%) but higher drug costs. A 3-year time horizon yielded similar results, but the absolute difference in total costs was smaller (SGLT2i $41,000 vs. GLP-1RA $57,000). ConCluSionS: In the short-term, SGLT2i are cost-effective compared to GLP-1RA. Treatment with these agents for a longer time horizon may yield differences in diabetes-related outcomes that may affect their cost-effectiveness, but these differences may not have been captured from a short US payer perspective.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.